B
Bull
Bull · 25%SPRC
$7.05
Szenariopreis
$6.580
-0.039 (-0.60%)Zum Schluss
Loading chart…
- High
- 6.820
- Open
- 6.750
- VWAP
- 6.63
- Vol
- 84.13K
- Mkt Cap
- 2.77M
- Low
- 6.500
- Amount
- 558.07K
- EV/EBITDA, TTM
- 0.00
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
AI analysis of Scisparc Ltd (SPRC)
holdCurrently, SciSparc Ltd (SPRC) is not a strong buy. The stock is trading at $6.58, which is significantly down 47.78% year-to-date and 70.04% over the past year. The RSI is at 43.72, indicating it is nearing oversold territory but not quite there yet. The forward P/E ratio is 0, suggesting uncertainty about future earnings, while the gross margin is relatively high at 78.09%, indicating potential for profitability if revenues can be stabilized. However, the negative net margin of -2041.65% raises concerns about current financial health. The main risk is the significant decline in stock price, which could continue if the company does not improve its financial performance or if market sentiment remains negative.
Bewertungskennzahlen
The current forward P/E ratio for Scisparc Ltd (SPRC) is 0.00, compared to its 5-year average forward P/E of -11.29.
Alphio AI Price Scenarios for SPRC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
4.508-26NewsfilterSciSparc Appoints AI Expert to Strengthen Strategic Focus
- 8.508-12Newsfilter
NeuroThera Secures Japanese Patent for Pain Treatment
9.008-05GlobenewswireSciSparc Initiates NeuroThera Phase IIb Clinical Trial
- 3.507-31Newsfilter
SciSparc and NeuroThera Achieve Technological Milestone
2.007-30NASDAQ.COMBiotech Companies See Significant Stock Gains
SPRC FAQ — answered by Alphio AI
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, SciSparc Ltd (SPRC) is not a strong buy. The stock is trading at $6.58, which is significantly down 47.78% year-to-date and 70.04% over the past year. The RSI is at 43.72, indicating it is nearing oversold territory but not quite there yet. The forward P/E ratio is 0, suggesting uncertainty about future earnings, while the gross margin is relatively high at 78.09%, indicating potential for profitability if revenues can be stabilized. However, the negative net margin of -2041.65% raises concerns about current financial health. The main risk is the significant decline in stock price, which could continue if the company does not improve its financial performance or if market sentiment remains negative.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.